Andrx abandons brand-name drug business

Share this article:
Andrx is selling off its brand-name pharmaceutical business and ending its supply and distribution contract with Pfizer for its hypertension drug Cardura XL.
Andrx decided to shed its brand-name division to focus on development and distribution. The company will end its contract with Pfizer for Cardura XL because the drug failed to win FDA approval by Dec. 31. Andrx is seeking a refund of the $10 million it paid Pfizer in connection with the agreement for Cardura XL, exercising its right to end the November 2003 deal.
Andrx retained Banc of America Securities to seek offers for its brand-name business, which sustained operating losses of about $31 million for the first nine months of 2004.
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.